Eric Lefkofsky Is Founder Of Tempus

Eric Lefkofsky is an businessmen and philanthropist known for founding a number of successful tech companies including Groupon, Echo Global Logistics, and Lightbank. In addition, Eric Lefkofsky is the co-founder and CEO of Tempus.

 

Tempus is a biotechnology company that uses computer analysis to better treat cancer. This is a four set process with Tempus providing innovative technology at each step. These steps include sequencing DNA for cancer, analyzing with revolutionary computer software, reporting the results to doctors, and then confirming the test results. This process allows cancer to be diagnosed early with results that provide insights into the best treatment.  More on adrinkwith.com.

 

The treatment options offered by Tempus are tailored to the specific patient and their cancer. This not only allows for a better outcome but can also result in the patient experiencing less side effects, and allows for the doctor to anticipate new develops in the patient’s individual cancers.

 

Tempus works with a number of prestigious institutes to develop and deliver its revolutionary technology. This includes the Mayo Clinic, Penn Medicine, Northwest Medicine, and the Pancreatic Cancer Action Network. These providers have a long history of working in cancer treatment, and have allowed Tempus to gather a large database on many different types of cancer.  Based on bizjournals.com

 

Eric Lefkofsky plans to continue his work with Tempus with the intention of greatly reducing the morbidity of cancer. In the future, Tempus plans to expand its genome database in order to provide even more accurate cancer tests. In addition, it has developed technologies that allow individual doctors to view its genetic test results. These results mean that the doctor can examine it themselves, and will allow the genetic test results to stay with the patient as they meet with specialist doctors. The ability to have accurate and useful genetic information stay with a patient is a game changer in cancer treatment that will soon become standard practice.

Follow his blogs on https://twitter.com/lefkofsky